PharmaVentures is pleased to announce that it provided transaction support to NovioGendix in its sale to MDxHealth SA (Euronext: MDXH.BR).

NovioGendix, a privately-held molecular diagnostics company focused on the development of a non-invasive liquid biopsy test for prostate cancer. It’s proprietary urine-based, molecular biomarker test for prostate cancer offers a low cost “liquid biopsy” method to identify patients at low risk for prostate cancer. This mRNA biomarker test can also help identify men at increased risk of high-grade disease who may benefit most from a prostate biopsy procedure.

Nigel Borshell, Vice President, PharmaVentures, Ltd said: “We are delighted to support NovioGendix and its shareholders in achieving an exit.”

Fintan Walton, Chief Executive, PharmaVentures, Ltd said: “This is another important result for one of our clients. PharmaVentures has established itself as a leading an advisor in M&A and Licensing”.

For the past 23 years, PharmaVentures has acted as advisor to over 700 global pharmaceutical and biotechnology clients in transactions; covering licensing, mergers, acquisitions, divestments and joint venture activities for companies.